Compare Quest Diagnostics Inc (DGX) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs ON Holding AG — how do they compare? Quest Diagnostics Inc trades at $230.98 (market cap $25.48B), while ON Holding AG trades at $34.79 (market cap $11.38B). The key difference: Quest Diagnostics Inc is far larger — about 2.2× ON Holding AG's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while ON Holding AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and ON Holding AG for 22 Days on average.
| DGX | ONON | |
|---|---|---|
Market Cap | $25.48B | $11.38B |
Volume | 941,866 | 13,732,872 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $50.63 |
52-Week Low | $173.49 | $26.76 |
Typical Hold Time | 56 Days | 22 Days |
Enterprise Value | $31.23B | $10.54B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
ONON trades at $34.79, up 4.73% today, reflecting strong momentum. The stock shows bullish technical signals with support at $33 and resistance at $35. Fundamentally, the company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $0.44 exceeding expectations. Revenue reached $3.01 billion in 2025, with a net income margin of 12.3%. Recent news highlights a $1 billion share buyback plan and ambitious 2029 targets.
The outlook is positive, driven by earnings growth, strategic expansion, and strong analyst support. Key risks include competitive pressures and market volatility. Analysts maintain a consensus buy rating with a $42.26 price target, suggesting potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
